T. Rowe Price Investment Management
HAE icon

T. Rowe Price Investment Management’s Haemonetics HAE Stock Holding History

T. Rowe Price Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.6M Buy
1,101,371
+504,216
+84% +$32.4M 0.05% 307
2026
Q1 		$33.7M Sell
597,155
-346,030
-37% -$22.5M 0.02% 403
2025
Q4 		$75.6M Sell
943,185
-67,772
-7% -$4.55M 0.05% 294
2025
Q3 		$49.3M Sell
1,010,957
-583,910
-37% -$36.1M 0.03% 392
2025
Q2 		$119M Sell
1,594,867
-600,702
-27% -$39.8M 0.08% 248
2025
Q1 		$140M Sell
2,195,569
-358,245
-14% -$24.4M 0.09% 222
2024
Q4 		$199M Sell
2,553,814
-296,823
-10% -$23.8M 0.12% 179
2024
Q3 		$229M Buy
2,850,637
+1,207,696
+74% +$97.6M 0.14% 168
2024
Q2 		$136M Buy
1,642,941
+424,730
+35% +$37.4M 0.09% 233
2024
Q1 		$104M Buy
1,218,211
+125,912
+12% +$9.88M 0.06% 287
2023
Q4 		$93.4M Buy
1,092,299
+245,382
+29% +$21.2M 0.06% 285
2023
Q3 		$75.9M Buy
+846,917
New +$75.6M 0.05% 297

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management's HAE Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Haemonetics (HAE) stake by 84% in Q2 2026, buying an estimated $32.4M and bringing the position to 1,101,371 shares worth $82.6M. The position accounts for 0.05% of the portfolio, ranked #307.

T. Rowe Price Investment Management first reported a position in HAE in Q3 2023 and has held it in 12 quarters since. The position peaked at $229M in Q3 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • T. Rowe Price Investment Management held 1,101,371 shares of Haemonetics worth $82.6M as of Q2 2026.
  • T. Rowe Price Investment Management bought 504,216 Haemonetics shares in Q2 2026, an estimated $32.4M.
  • Haemonetics made up 0.05% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #307 holding.
  • T. Rowe Price Investment Management first reported a position in Haemonetics in Q3 2023 and has held it in 12 quarters since.
  • T. Rowe Price Investment Management's Haemonetics position peaked at $229M in Q3 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.